Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a pre-investigational new drug (IND) meeting for its lead asset POLB 001. POLB 001 is being developed as a potential preventative therapy for cytokine release syndrome (CRS), a serious side effect triggered by cancer immunotherapy treatments.